Vivo Capital Viii, Llc - Net Worth and Insider Trading
Vivo Capital Viii, Llc Net Worth
The estimated net worth of Vivo Capital Viii, Llc is at least $16 Million dollars as of 2024-09-20. Vivo Capital Viii, Llc is the 10% Owner of Crinetics Pharmaceuticals Inc and owns about 294,357 shares of Crinetics Pharmaceuticals Inc (CRNX) stock worth over $16 Million. Vivo Capital Viii, Llc is the 10% Owner of BioPharmX Corp and owns about 26,439 shares of BioPharmX Corp (BPMX) stock worth over $161,807. Vivo Capital Viii, Llc is also the 10% Owner of Nabriva Therapeutics PLC and owns about 16,297 shares of Nabriva Therapeutics PLC (NBRVF) stock worth over $2. Details can be seen in Vivo Capital Viii, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Capital Viii, Llc has not made any transactions after 2019-06-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Vivo Capital Viii, Llc
Vivo Capital Viii, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vivo Capital Viii, Llc owns 9 companies in total, including Aligos Therapeutics Inc (ALGS) , Crinetics Pharmaceuticals Inc (CRNX) , and Trex Wind Down Inc (TMBRQ) among others .
Click here to see the complete history of Vivo Capital Viii, Llc’s form 4 insider trades.
Insider Ownership Summary of Vivo Capital Viii, Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2020-10-15 | 10 percent owner |
| CRNX | Crinetics Pharmaceuticals Inc | 2020-01-29 | 10 percent owner |
| TMBRQ | Trex Wind Down Inc | 2019-06-25 | 10 percent owner |
 | | 2019-01-07 | 10 percent owner |
| | 2018-01-24 | 10 percent owner |
| | 2017-09-18 | 10 percent owner |
| | 2021-04-22 | 10 percent owner |
| | 2021-02-04 | 10 percent owner |
| | 2022-08-12 | 10 percent owner |
Vivo Capital Viii, Llc Latest Holdings Summary
Vivo Capital Viii, Llc currently owns a total of 3 stocks. Among these stocks, Vivo Capital Viii, Llc owns 294,357 shares of Crinetics Pharmaceuticals Inc (CRNX) as of July 20, 2018, with a value of $16 Million and a weighting of 98.99%. Vivo Capital Viii, Llc owns 26,439 shares of BioPharmX Corp (BPMX) as of June 25, 2019, with a value of $161,807 and a weighting of 1.01%. Vivo Capital Viii, Llc also owns 16,297 shares of Nabriva Therapeutics PLC (NBRVF) as of September 18, 2017, with a value of $2 and a weighting of 0%.
Latest Holdings of Vivo Capital Viii, Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals Inc | 2018-07-20 | 294,357 | 53.91 | 15,868,786 |
| BPMX | BioPharmX Corp | 2019-06-25 | 26,439 | 6.12 | 161,807 |
| NBRVF | Nabriva Therapeutics PLC | 2017-09-18 | 16,297 | 0.00 | 2 |
Holding Weightings of Vivo Capital Viii, Llc
Vivo Capital Viii, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Vivo Capital Viii, Llc has made a total of 0 transactions in Crinetics Pharmaceuticals Inc (CRNX) over the past 5 years. The most-recent trade in Crinetics Pharmaceuticals Inc is the acquisition of 353,180 shares on July 20, 2018, which cost Vivo Capital Viii, Llc around $7 Million.
According to the SEC Form 4 filings, Vivo Capital Viii, Llc has made a total of 0 transactions in BioPharmX Corp (BPMX) over the past 5 years. The most-recent trade in BioPharmX Corp is the sale of 27,322 shares on June 25, 2019, which brought Vivo Capital Viii, Llc around $334,427.
According to the SEC Form 4 filings, Vivo Capital Viii, Llc has made a total of 0 transactions in Nabriva Therapeutics PLC (NBRVF) over the past 5 years. The most-recent trade in Nabriva Therapeutics PLC is the acquisition of 211 shares on September 18, 2017, which cost Vivo Capital Viii, Llc around $497,889.
Insider Trading History of Vivo Capital Viii, Llc
- 1
Vivo Capital Viii, Llc Trading Performance
GuruFocus tracks the stock performance after each of Vivo Capital Viii, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Capital Viii, Llc is -17.79%. GuruFocus also compares Vivo Capital Viii, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Capital Viii, Llc within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Vivo Capital Viii, Llc's insider trading performs compared to the benchmark.
Performance of Vivo Capital Viii, Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.26 | | | | | |
| Relative Return to S&P 500(%) | 5.13 | | | | | |
Vivo Capital Viii, Llc Ownership Network
Vivo Capital Viii, Llc Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Vivo Capital Viii, Llc is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Vivo Capital Viii, Llc made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 317,344 shares were bought by its insiders, resulting in a net purchase of 317,344 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Vivo Capital Viii, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Vivo Capital Viii, Llc. You might contact Vivo Capital Viii, Llc via mailing address: 192 Lytton Avenue, Palo Alto Ca 94301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
